Burkitt Lymphoma · line 1 · Dose-modified R-CODOX-M / R-IVAC: high-risk reference without proven CNS disease (eviQ 4489/4490)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | aggressive |
| Linked regimen | REG-CODOX-M-IVAC |
| ID | IND-BURKITT-1L-CODOXM-IVAC |
|---|---|
| Type | Indication |
| Status | pending_clinical_signoff |
| Diseases | DIS-BURKITT |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-EVIQ-BURKITT-OVERVIEW-3727 SRC-NCCN-BCELL-2025 |
Notes
Positive risk/CNS confirmation guard only. Demographic eligibility, biomarkers, efficacy estimates, current-line ranking and CNS-specific or low-risk protocol implementation remain unreviewed.
Used By
Algorithms
ALGO-BURKITT-1L- ALGO-BURKITT-1L